Project/Area Number |
09670498
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
内科学一般
|
Research Institution | Aichi Medical University |
Principal Investigator |
SUGIYAMA Hirotaka Aichi Medical University, Internal Medicine, Assitant Professor, 医学部, 講師 (70242112)
|
Co-Investigator(Kenkyū-buntansha) |
FUKUZAWA Yoshitaka Aichi Medical University, Internal Medicine, Assitant Professor, 医学部, 講師 (50218905)
石川 哲也 愛知医科大学, 医学部, 助手 (10288508)
各務 伸一 愛知医科大学, 医学部, 教授 (10115545)
|
Project Period (FY) |
1997 – 1998
|
Project Status |
Completed (Fiscal Year 1998)
|
Budget Amount *help |
¥3,200,000 (Direct Cost: ¥3,200,000)
Fiscal Year 1998: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 1997: ¥2,300,000 (Direct Cost: ¥2,300,000)
|
Keywords | viral persistent infection / hepatic cancer / gene therapy / HCV / antioncogene / killer T cell / signal transduction / immunology / 核構造 / HCC / 感染免疫 / p53 / AFP / B7 / ribosome S6 kinase |
Research Abstract |
Human persistently infectious viruses (HIV, HTLV, HCV, HBV and so on) are broadly epidemic all over the world. We attempted to establish a therapeutic model of persistently infectious virus using HCV and hepatic cancer. We first analyzed to identify the toxic element of HCV, and then, established the methods of reactivation of inactive T cell by using B7. Following these experiment, we established the therapeutic methods of activation of the apoptotic signal of cancer cells. In this research, we identified toxic element of the virus and novel epitope of hepatic cancer, established T cell line recognizing hepatic cancer and therapeutic vector against cancer.
|